{"id":"NCT00912964","sponsor":"Astellas Pharma Inc","briefTitle":"A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","officialTitle":"A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04-28","primaryCompletion":"2010-04-27","completion":"2010-04-27","firstPosted":"2009-06-03","resultsPosted":"2012-10-17","lastUpdate":"2024-11-21"},"enrollment":2030,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Urinary Bladder, Overactive"],"interventions":[{"type":"DRUG","name":"Mirabegron","otherNames":["YM178","Myrebtriq"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Mirabegron 25 mg","type":"EXPERIMENTAL"},{"label":"Mirabegron 50 mg","type":"EXPERIMENTAL"}],"summary":"The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.","primaryOutcome":{"measure":"Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-0.96,"sd":0.122},{"arm":"Mirabegron 25 mg","deltaMin":-1.36,"sd":0.124},{"arm":"Mirabegron 50 mg","deltaMin":-1.38,"sd":0.123}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"},{"comp":"OG000 vs OG002","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":151,"countries":["United States","Canada","Czechia","Denmark","Finland","Germany","Hungary","Norway","Slovakia","Spain","Sweden"]},"refs":{"pmids":["24246044","23769122"],"seeAlso":["https://www.astellasclinicalstudyresults.com/study.aspx?ID=26"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":433},"commonTop":["Hypertension","Nasopharyngitis"]}}